Short-Term Changes in Serum Potassium and the Risk of Subsequent Vascular Events and Mortality: Results from a Randomized Controlled Trial of ACE Inhibitors

CONCLUSIONS: Continuation of angiotensin-converting enzyme inhibitor-based therapy consistently decreased the subsequent risk of clinical outcomes, including cardiovascular and kidney outcomes and death, regardless of short-term changes in serum potassium.CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE), NCT00145925.PMID:35896277 | DOI:10.2215/CJN.00180122

Source: Clinical Journal of the American Society of Nephrology : CJASN - July 27, 2022 Category: Urology & Nephrology Authors: Toshiaki Ohkuma Katie Harris Mark Cooper Diederick E Grobbee Pavel Hamet Stephen Harrap Giuseppe Mancia Michel Marre Anushka Patel Anthony Rodgers Bryan Williams Mark Woodward John Chalmers ADVANCE Collaborative Group Source Type: research